JP2009515836A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515836A5 JP2009515836A5 JP2008539089A JP2008539089A JP2009515836A5 JP 2009515836 A5 JP2009515836 A5 JP 2009515836A5 JP 2008539089 A JP2008539089 A JP 2008539089A JP 2008539089 A JP2008539089 A JP 2008539089A JP 2009515836 A5 JP2009515836 A5 JP 2009515836A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- formula
- composition
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 96
- 238000000034 method Methods 0.000 claims 35
- 239000000203 mixture Substances 0.000 claims 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 26
- 239000007787 solid Substances 0.000 claims 26
- 239000002904 solvent Substances 0.000 claims 24
- 239000003814 drug Substances 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 238000002329 infrared spectrum Methods 0.000 claims 14
- 229940124597 therapeutic agent Drugs 0.000 claims 14
- -1 6-Fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl Chemical group 0.000 claims 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 12
- 206010002388 Angina unstable Diseases 0.000 claims 11
- 208000007814 Unstable Angina Diseases 0.000 claims 11
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 11
- 238000000634 powder X-ray diffraction Methods 0.000 claims 11
- 241000124008 Mammalia Species 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 10
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 9
- 206010000891 acute myocardial infarction Diseases 0.000 claims 9
- 239000013078 crystal Substances 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 230000000302 ischemic effect Effects 0.000 claims 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 8
- 239000003146 anticoagulant agent Substances 0.000 claims 8
- 210000004351 coronary vessel Anatomy 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 238000001356 surgical procedure Methods 0.000 claims 8
- 208000007718 Stable Angina Diseases 0.000 claims 7
- 208000006011 Stroke Diseases 0.000 claims 7
- 208000007536 Thrombosis Diseases 0.000 claims 7
- 238000002399 angioplasty Methods 0.000 claims 7
- 238000013172 carotid endarterectomy Methods 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 238000001035 drying Methods 0.000 claims 6
- 238000010438 heat treatment Methods 0.000 claims 6
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 5
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 5
- 208000005189 Embolism Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 229940100389 Sulfonylurea Drugs 0.000 claims 5
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 5
- 206010047249 Venous thrombosis Diseases 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 5
- 230000002068 genetic effect Effects 0.000 claims 5
- 238000003780 insertion Methods 0.000 claims 5
- 230000037431 insertion Effects 0.000 claims 5
- 201000011461 pre-eclampsia Diseases 0.000 claims 5
- 201000005665 thrombophilia Diseases 0.000 claims 5
- 230000001732 thrombotic effect Effects 0.000 claims 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims 4
- 230000000702 anti-platelet effect Effects 0.000 claims 4
- 229940127219 anticoagulant drug Drugs 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 238000007887 coronary angioplasty Methods 0.000 claims 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 4
- YPHXEBPBOGJRII-UHFFFAOYSA-N potassium;sulfonylurea Chemical compound [K].NC(=O)N=S(=O)=O YPHXEBPBOGJRII-UHFFFAOYSA-N 0.000 claims 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 4
- 238000007631 vascular surgery Methods 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- 238000010521 absorption reaction Methods 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 230000002490 cerebral effect Effects 0.000 claims 3
- 208000029078 coronary artery disease Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 230000001052 transient effect Effects 0.000 claims 3
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims 2
- WUPZRLYEGIXBNO-UHFFFAOYSA-N 1-(5-chlorothiophen-2-yl)sulfonyl-1-[4-[6-fluoro-7-(methylamino)-2,4-dioxo-1h-quinazolin-3-yl]phenyl]urea Chemical compound O=C1C=2C=C(F)C(NC)=CC=2NC(=O)N1C(C=C1)=CC=C1N(C(N)=O)S(=O)(=O)C1=CC=C(Cl)S1 WUPZRLYEGIXBNO-UHFFFAOYSA-N 0.000 claims 2
- QHFUNOSLYOQGKO-UHFFFAOYSA-N 1-(5-chlorothiophen-2-yl)sulfonyl-1-[4-[6-fluoro-7-(methylamino)-2,4-dioxo-1h-quinazolin-3-yl]phenyl]urea;potassium Chemical compound [K].O=C1C=2C=C(F)C(NC)=CC=2NC(=O)N1C(C=C1)=CC=C1N(C(N)=O)S(=O)(=O)C1=CC=C(Cl)S1 QHFUNOSLYOQGKO-UHFFFAOYSA-N 0.000 claims 2
- HQKSVTNOXNXOGZ-UHFFFAOYSA-N 1-(5-chlorothiophen-2-yl)sulfonyl-1-[4-[6-fluoro-7-(methylamino)-2,4-dioxo-1h-quinazolin-3-yl]phenyl]urea;sodium Chemical compound [Na].O=C1C=2C=C(F)C(NC)=CC=2NC(=O)N1C(C=C1)=CC=C1N(C(N)=O)S(=O)(=O)C1=CC=C(Cl)S1 HQKSVTNOXNXOGZ-UHFFFAOYSA-N 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- 206010022562 Intermittent claudication Diseases 0.000 claims 2
- 229910002651 NO3 Inorganic materials 0.000 claims 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims 2
- 239000000006 Nitroglycerin Substances 0.000 claims 2
- 206010038563 Reocclusion Diseases 0.000 claims 2
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims 2
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 2
- 206010043647 Thrombotic Stroke Diseases 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- 230000010933 acylation Effects 0.000 claims 2
- 238000005917 acylation reaction Methods 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000008052 alkyl sulfonates Chemical class 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003529 anticholesteremic agent Substances 0.000 claims 2
- 229940127226 anticholesterol agent Drugs 0.000 claims 2
- 239000003420 antiserotonin agent Substances 0.000 claims 2
- 125000005228 aryl sulfonate group Chemical group 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 229940072645 coumadin Drugs 0.000 claims 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 2
- 239000003527 fibrinolytic agent Substances 0.000 claims 2
- 229960003711 glyceryl trinitrate Drugs 0.000 claims 2
- 229960002897 heparin Drugs 0.000 claims 2
- 229920000669 heparin Polymers 0.000 claims 2
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 2
- 229940118179 lovenox Drugs 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 229940126409 proton pump inhibitor Drugs 0.000 claims 2
- 239000000612 proton pump inhibitor Substances 0.000 claims 2
- 150000003246 quinazolines Chemical class 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 230000002441 reversible effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- BBZGPVLOWDIXCM-UHFFFAOYSA-N sodium;sulfonylurea Chemical compound [Na].NC(=O)N=S(=O)=O BBZGPVLOWDIXCM-UHFFFAOYSA-N 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 239000003868 thrombin inhibitor Substances 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 2
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 claims 1
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 claims 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 claims 1
- 229940123987 Thromboxane A2 receptor antagonist Drugs 0.000 claims 1
- 102000003938 Thromboxane Receptors Human genes 0.000 claims 1
- 108090000300 Thromboxane Receptors Proteins 0.000 claims 1
- WLMZTKAZJUWXCB-KQYNXXCUSA-N [(2r,3s,4r,5r)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate Chemical compound C12=NC(SC)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O WLMZTKAZJUWXCB-KQYNXXCUSA-N 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 239000002473 artificial blood Substances 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000007971 neurological deficit Effects 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 claims 1
- 0 CC=[S@](c([s]1)ccc1Cl)NC(Nc(cc1)ccc1N(C(c1cc(*)c(*)cc1N1)=O)C1=O)=O Chemical compound CC=[S@](c([s]1)ccc1Cl)NC(Nc(cc1)ccc1N(C(c1cc(*)c(*)cc1N1)=O)C1=O)=O 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73365005P | 2005-11-03 | 2005-11-03 | |
| US60/733,650 | 2005-11-03 | ||
| PCT/US2006/043093 WO2007056219A2 (en) | 2005-11-03 | 2006-11-03 | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009515836A JP2009515836A (ja) | 2009-04-16 |
| JP2009515836A5 true JP2009515836A5 (enExample) | 2010-12-09 |
| JP5509406B2 JP5509406B2 (ja) | 2014-06-04 |
Family
ID=38023842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008539089A Active JP5509406B2 (ja) | 2005-11-03 | 2006-11-03 | ［４−（６−ハロ−７−置換−２，４−ジオキソ−１，４−ジヒドロ−２ｈ−キナゾリン−３−イル）−フェニル］−５−クロロ−チオフェン−２−イル−スルホニル尿素、ならびにそれに関連する形態および方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20070208045A1 (enExample) |
| EP (2) | EP1951254B1 (enExample) |
| JP (1) | JP5509406B2 (enExample) |
| KR (1) | KR101423483B1 (enExample) |
| CN (1) | CN101300013B (enExample) |
| AR (1) | AR056762A1 (enExample) |
| AT (1) | ATE540034T1 (enExample) |
| AU (1) | AU2006311795B2 (enExample) |
| BR (1) | BRPI0618210A2 (enExample) |
| CA (1) | CA2627719C (enExample) |
| CY (1) | CY1112826T1 (enExample) |
| DK (1) | DK1951254T3 (enExample) |
| EA (1) | EA017402B1 (enExample) |
| ES (1) | ES2380814T3 (enExample) |
| IL (1) | IL191193A (enExample) |
| NZ (2) | NZ567747A (enExample) |
| PT (1) | PT1951254E (enExample) |
| TW (2) | TW200728260A (enExample) |
| WO (2) | WO2007056219A2 (enExample) |
| ZA (1) | ZA200804241B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101195801B1 (ko) | 2004-06-18 | 2012-11-05 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｘａ 인자 억제제 |
| CA2627719C (en) | 2005-11-03 | 2016-07-12 | Portola Pharmaceuticals, Inc. | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
| EP2016072B1 (en) | 2006-05-05 | 2014-07-16 | Millennium Pharmaceuticals, Inc. | Factor xa inhibitors |
| WO2008133155A1 (ja) | 2007-04-19 | 2008-11-06 | Astellas Pharma Inc. | 二環式ヘテロ環化合物 |
| US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
| CA2686221A1 (en) * | 2007-05-02 | 2008-11-13 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
| KR101509829B1 (ko) * | 2007-05-02 | 2015-04-06 | 포톨라 파마슈티컬스, 인코포레이티드 | 혈소판 ａｄｐ 수용체 억제제로 작용하는 화합물을 이용한 병용요법 |
| US20090048216A1 (en) | 2007-05-02 | 2009-02-19 | Portola Pharmaceuticals, Inc. | Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor |
| MX2009013431A (es) * | 2007-06-18 | 2010-01-15 | Sanofi Aventis | Derivados de pirrol como antagonistas de p2y12. |
| CN101654441B (zh) * | 2008-08-19 | 2012-10-03 | 信谊药厂 | 抗凝化合物、组合物及其用途 |
| RU2011123377A (ru) * | 2008-11-14 | 2012-12-20 | Портола Фармасьютиклз, Инк. | ТВЕРДАЯ КОМПОЗИЦИЯ ДЛЯ КОНТРОЛИРУЕМОГО ВЫСВОБОЖДЕНИЯ АКТИВНЫХ ИОНИЗИРУЕМЫХ АГЕНТОВ, ХАРАКТЕРИЗУЮЩИХСЯ НИЗКОЙ РАСТВОРИМОСТЬЮ В ВОДЕ ПРИ НИЗКИХ ЗНАЧЕНИЯХ pН, И СПОСОБЫ ЕЕ ПРИМЕНЕНИЯ |
| WO2011006169A1 (en) | 2009-07-10 | 2011-01-13 | Portola Pharmaceuticals, Inc. | Methods for diagnosis and treatment of thrombotic disorders mediated by cyp2c19*2 |
| JP5597202B2 (ja) | 2009-08-28 | 2014-10-01 | 第一三共株式会社 | ３−（ビアリールオキシ）プロピオン酸誘導体 |
| EP2513094B1 (en) | 2009-12-17 | 2015-12-16 | Millennium Pharmaceuticals, Inc. | Crystalline salts of a factor xa inhibitor |
| US8742120B2 (en) | 2009-12-17 | 2014-06-03 | Millennium Pharmaceuticals, Inc. | Methods of preparing factor xa inhibitors and salts thereof |
| WO2011088152A1 (en) | 2010-01-12 | 2011-07-21 | Portola Pharmaceuticals, Inc. | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
| WO2011137459A1 (en) | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
| JP2013544271A (ja) * | 2010-12-03 | 2013-12-12 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 式（ｉ）の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法 |
| JP6268093B2 (ja) * | 2012-09-14 | 2018-01-24 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
| RU2556198C1 (ru) * | 2014-04-10 | 2015-07-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук | Способ профилактики развития постперикардиотомного синдрома у больных ишемической болезнью сердца, подвергшихся коронарному шунтированию |
| US9957267B2 (en) | 2015-07-01 | 2018-05-01 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| WO2019023278A1 (en) | 2017-07-25 | 2019-01-31 | Crinetics Pharmaceuticals, Inc. | MODULATORS OF SOMATOSTATIN AND USES THEREOF |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE845042C (de) | 1950-07-14 | 1952-07-28 | Basf Ag | Verfahren zur Herstellung von Sulfonylurethanen, -harnstoffen oder -carbonsaeureamiden |
| US3847925A (en) * | 1971-07-15 | 1974-11-12 | En Nom Collectif Science Et Ci | Benzenesulfonyl semicarbazides |
| DE3134780A1 (de) * | 1981-09-02 | 1983-03-10 | Hoechst Ag, 6000 Frankfurt | "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung" |
| US4720450A (en) * | 1985-06-03 | 1988-01-19 | Polaroid Corporation | Thermal imaging method |
| GB9413975D0 (en) | 1994-07-11 | 1994-08-31 | Fujisawa Pharmaceutical Co | New heterobicyclic derivatives |
| US5314902A (en) * | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
| US6268380B1 (en) | 1993-02-19 | 2001-07-31 | G. D. Searle & Co. | Urea derivatives useful as platelet aggregation inhibitors |
| WO1994021602A1 (en) | 1993-03-15 | 1994-09-29 | G.D. Searle & Co. | Urea derivatives useful as platelet aggregation inhibitors |
| JPH0881442A (ja) | 1994-07-14 | 1996-03-26 | Otsuka Pharmaceut Co Ltd | 環状アミド誘導体 |
| TW448161B (en) | 1994-07-14 | 2001-08-01 | Otsuka Pharma Co Ltd | Cyclic amide derivatives |
| US6413724B1 (en) | 1996-10-28 | 2002-07-02 | Versicor, Inc. | Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones |
| US6160000A (en) * | 1996-12-23 | 2000-12-12 | Merck & Co., Inc. | Antidiabetic agents based on aryl and heteroarylacetic acids |
| JPH10195323A (ja) | 1997-01-09 | 1998-07-28 | Nippon Paper Ind Co Ltd | 新規なスルホニルグアニジン化合物及びそれを用いた感熱記録体 |
| SE9702774D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
| CA2318199A1 (en) | 1998-01-15 | 1999-07-22 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
| JP2000204081A (ja) | 1998-02-05 | 2000-07-25 | Takeda Chem Ind Ltd | スルホンアミド誘導体、その製造法及び用途 |
| US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| WO2001057037A1 (en) | 2000-02-04 | 2001-08-09 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
| DE60144284D1 (de) | 2000-11-01 | 2011-05-05 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
| US6824790B2 (en) * | 2002-01-09 | 2004-11-30 | Enzrel Inc. | Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds |
| US20040242658A1 (en) * | 2003-01-08 | 2004-12-02 | Dr. Reddy's Laboratories Limited | Amorphous form of rosiglitazone maleate and process for preparation thereof |
| PL1668002T3 (pl) * | 2003-10-03 | 2010-02-26 | Portola Pharm Inc | 2,4-diokso-3-chinazolinyloarylowe pochodne sulfonylomocznika |
| CA2627719C (en) * | 2005-11-03 | 2016-07-12 | Portola Pharmaceuticals, Inc. | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
| US20090048216A1 (en) * | 2007-05-02 | 2009-02-19 | Portola Pharmaceuticals, Inc. | Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor |
| US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
| CA2686221A1 (en) * | 2007-05-02 | 2008-11-13 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
-
2006
- 2006-11-03 CA CA2627719A patent/CA2627719C/en not_active Expired - Fee Related
- 2006-11-03 WO PCT/US2006/043093 patent/WO2007056219A2/en not_active Ceased
- 2006-11-03 NZ NZ567747A patent/NZ567747A/en not_active IP Right Cessation
- 2006-11-03 US US11/556,518 patent/US20070208045A1/en not_active Abandoned
- 2006-11-03 TW TW095140749A patent/TW200728260A/zh unknown
- 2006-11-03 CN CN2006800410635A patent/CN101300013B/zh not_active Expired - Fee Related
- 2006-11-03 NZ NZ596025A patent/NZ596025A/xx not_active IP Right Cessation
- 2006-11-03 DK DK06827506.4T patent/DK1951254T3/da active
- 2006-11-03 KR KR1020087013178A patent/KR101423483B1/ko not_active Expired - Fee Related
- 2006-11-03 TW TW095140753A patent/TWI397529B/zh not_active IP Right Cessation
- 2006-11-03 AT AT06827506T patent/ATE540034T1/de active
- 2006-11-03 PT PT06827506T patent/PT1951254E/pt unknown
- 2006-11-03 EP EP06827506A patent/EP1951254B1/en active Active
- 2006-11-03 EP EP11176014A patent/EP2428514A1/en not_active Withdrawn
- 2006-11-03 ZA ZA200804241A patent/ZA200804241B/xx unknown
- 2006-11-03 BR BRPI0618210-0A patent/BRPI0618210A2/pt not_active Application Discontinuation
- 2006-11-03 EA EA200801245A patent/EA017402B1/ru not_active IP Right Cessation
- 2006-11-03 US US11/556,490 patent/US8058284B2/en active Active
- 2006-11-03 AU AU2006311795A patent/AU2006311795B2/en not_active Ceased
- 2006-11-03 AR ARP060104840A patent/AR056762A1/es unknown
- 2006-11-03 WO PCT/US2006/042998 patent/WO2007056167A2/en not_active Ceased
- 2006-11-03 ES ES06827506T patent/ES2380814T3/es active Active
- 2006-11-03 JP JP2008539089A patent/JP5509406B2/ja active Active
-
2008
- 2008-05-01 IL IL191193A patent/IL191193A/en not_active IP Right Cessation
-
2011
- 2011-10-11 US US13/271,037 patent/US20120088736A1/en not_active Abandoned
-
2012
- 2012-04-04 CY CY20121100393T patent/CY1112826T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020203464B2 (en) | Sulfonylureas and related compounds and use of same | |
| CA2829790C (en) | Multisubstituted aromatic compounds as inhibitors of thrombin | |
| JP4657384B2 (ja) | ナトリウムチャンネルモジュレーターとしての２−ピリジンカルボキサミド誘導体 | |
| JP3335362B2 (ja) | キノレイン−２（１ｈ）−オン誘導体セロトニンアンタゴニスト | |
| JPH05508660A (ja) | ジアリールメチルピペリジンまたはピペラジンのピリジンおよびピリジンｎ−オキシド誘導体、並びにそれらの組成物および使用方法 | |
| PL214701B1 (pl) | Pochodna piperydyny, kompozycja farmaceutyczna zawierajaca te pochodna oraz zastosowanie lecznicze tej pochodnej | |
| TW200402294A (en) | Chemical compounds | |
| TW200815426A (en) | New pyridine analogues II 333 | |
| JPH11511161A (ja) | オキシド−スクアレンサイクラーゼ阻害剤の血中コレステロールを低下させるための使用 | |
| JPH02218668A (ja) | キナゾリン、その製法及び該化合物を含有する抗腫瘍作用を有する医薬組成物 | |
| EP2138482A1 (en) | Bicyclic heterocyclic compound | |
| JP2008502628A (ja) | ピリダジン−３（２ｈ）−オン誘導体およびｐｄｅ４の阻害剤としてのそれらの使用 | |
| SK61399A3 (en) | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | |
| JP2008543956A (ja) | Ｒｈｏ−キナーゼの阻害剤としてのイソキノリン誘導体 | |
| TW200803852A (en) | Inhibitors of histone deacetylase for the treatment of disease | |
| JPH03130281A (ja) | 複素環式誘導体、その製造方法および前記誘導体を含有するロイコトリエン誘因性疾患または症状の治療に用いる薬理学的組成物 | |
| CN101652366A (zh) | 新型抗叶酸剂 | |
| TW201632504A (zh) | ２－（５－（３－氟苯基）－３－羥吡啶醯胺基）乙酸之固體形式、其組合物及其用途 | |
| MXPA06003625A (es) | Isoquinolinonas sustituidas. | |
| JP2010235635A (ja) | 多酸性塩基化合物の酸付加塩の製造方法 | |
| JP2009542641A (ja) | 新規ピリジン類縁体 | |
| JPH0471077B2 (enExample) | ||
| JP2010526105A5 (enExample) | ||
| TW200413367A (en) | Novel processes and intermediates for preparing triazolo-pyridines | |
| PL183867B1 (pl) | Nowe indazolokarboksyamidy, sposób ich wytwarzania i środek farmaceutyczny |